Development and validation of a risk prediction model for small intestinal mucosal injury in nonsteroidal
Ning-Hui Zhao1,2, Ling-Ran Zhao1, Jia Yao2
1Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China.
Background:
Despite the enhanced detection capability of capsule endoscopy for small intestinal lesions, the independent risk factors and distinct clinical-endoscopic characteristics in high-risk populations remain incompletely elucidated.
Aim:
To investigate the risk factors for small intestinal mucosal injury (SIMI) in nonsteroidal anti-inflammatory drug (NSAID) users and to establish a corresponding predictive model.
Methods:
We conducted a retrospective analysis of clinical data from patients undergoing capsule endoscopy at our institution and Shanxi Bethune Hospital from August 2012 to January 2025. Multivariate analysis was performed to identify independent risk factors for SIMI. A nomogram was subsequently developed to predict the risk of SIMI in NSAID users. Receiver operating characteristic curve analysis, calibration curve and decision curve analysis were performed to evaluate the predictive accuracy of the nomogram.
Results:
In the primary cohort, SIMI was identified in 114 out of 181 NSAID users. Multivariate analysis revealed that advanced age, smoking, proton pump inhibitor use, elevated body mass index, high triglyceride levels, and increased low-density lipoprotein were independent risk factors for SIMI. The research team developed a risk prediction model for estimating the risk of mucosal injury, which achieved an area under the curve of 0.775 (95% confidence interval: 0.700-0.849) in the derivation set. The model exhibited an area under the curve of 0.797 (95% confidence interval: 0.643-0.952) in the validation cohort.
Conclusion:
We identified risk factors for SIMI in NSAID users and established a predictive model, which may facilitate early identification of high-risk populations and guide clinical interventions.
Related Concept Videos
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors


